Ardelyx to Report First Quarter 2024 Financial Results on May 2, 2024
18 Aprile 2024 - 2:00PM
Ardelyx, Inc. (Nasdaq: ARDX), a biopharmaceutical company founded
with a mission to discover, develop and commercialize innovative,
first-in-class medicines that meet significant unmet medical needs,
today announced it will hold a conference call on Thursday, May 2,
2024, at 4:30 p.m. Eastern Time to discuss financial results and
provide a business update from the first quarter of 2024.
To participate in the conference call, please dial (844)
481-2838 (domestic) or (412) 317-1858 (international) and ask to be
joined into the Ardelyx call. Live audio of the conference call
will be simultaneously webcast and will be available under the
Investors section of the company's website
at www.ardelyx.com. The webcast will be archived and
available for replay for 30 days following the call.
About ArdelyxArdelyx was founded with a mission
to discover, develop and commercialize innovative, first-in-class
medicines that meet significant unmet medical needs. Ardelyx has
two commercial products approved in the United States, IBSRELA®
(tenapanor) and XPHOZAH® (tenapanor) as well as early-stage
pipeline candidates. Ardelyx has agreements for the development and
commercialization of tenapanor outside of the U.S. Kyowa Kirin
commercializes PHOZEVEL® (tenapanor) for hyperphosphatemia in
Japan. A New Drug Application for tenapanor for hyperphosphatemia
has been submitted in China with Fosun Pharma. Knight Therapeutics
commercializes IBSRELA in Canada. For more information, please
visit https://ardelyx.com/ and connect with us on X (formerly known
as Twitter), LinkedIn and Facebook.
Investor and Media Contacts: Caitlin
Lowieclowie@ardelyx.com
Grafico Azioni Ardelyx (NASDAQ:ARDX)
Storico
Da Apr 2024 a Mag 2024
Grafico Azioni Ardelyx (NASDAQ:ARDX)
Storico
Da Mag 2023 a Mag 2024